louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06328920: Intermittent Oro-esophageal Tube on Rehabilitation Therapy Compliance for Stroke
Official title: A Randomized Controlled Study to Explore the Effect of Intermittent Oro-esophageal Tube on Rehabilitation Therapy Compliance in Stroke Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Stroke
Lead sponsor: Chao Phya Abhaibhubejhr Hospital
Sponsor class: OTHER_GOV
First posted: 2024-03-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this clinical trial is to compare Rehabilitation Therapy Compliance of ischemic stroke patients who receive enteral nutrition support through either Intermittent Oro-esophageal Tube or Nasogastric Tube. Patients will be randomly assigned to either an observation group or a control group, with both groups receiving routine rehabilitation treatment. The observation group will receive enteral nutrition support through Intermittent Oro-esophageal Tube, while the control group will receive it through Nasogastric Tube. Researchers will then compare Rehabilitation Therapy Compliance of the two groups.

Detailed description: The study will last 15 days for each participant. The aim of this clinical trial is to compare Rehabilitation Therapy Compliance of ischemic stroke patients who receive enteral nutrition support through either Intermittent Oro-esophageal Tube or Nasogastric Tube. Patients will be randomly assigned to either an observation group or a control group, with both groups receiving routine rehabilitation treatment. The observation group will receive enteral nutrition support through Intermittent Oro-esophageal Tube, while the control group will receive it through Nasogastric Tube. Researchers will then compare Rehabilitation Therapy Compliance of the two groups.

Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years;
* meeting the diagnostic criteria of stroke;
* any degree of dysphagia at admission;
* steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment.
* transferred out within three weeks of hospitalization in the neurology department.

Exclusion Criteria:

* complicated with other neurological diseases;
* damaged mucosa or incomplete structure in nasopharynx;
* tracheostomy tube plugged;
* unfeasible to the support of parenteral nutrition;
* simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.

Primary outcomes:
measure: Rehabilitation Treatment Compliance Questionnaire
timeFrame: day 1 and day 15
Secondary outcomes:
measure: Patient Health Questionnaire-9
timeFrame: day 1 and day 15
measure: Swallowing Quality of Life questionnaire
timeFrame: day 1 and day 15
Other outcomes:
Locations:
Study officials:
affiliation: Site Coordinator of United Medical Group
name: Nieto Luis
role: STUDY_CHAIR
References:
Clinical trial NCT02495220: Efficacy of Dexmedetomidine for Postoperative Analgesia in Infantile Cataract Surgery
Official title: Subtenon Versus Intravenous Dexmedetomidine for Postoperative Analgesia and Vomiting Control in Infantile Cataract Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Postoperative Pain
Postoperative Vomiting
Keywords: dexmedetomidine
subtenon anesthesia
postoperative pain
pov
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2015-07-13
Enrollment: 80
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the present study was to evaluate the efficacy and safety of subtenon block (SB)anesthesia with dexmedetomidine in combination with bupivacaine versus intravenous dexmedetomidine for postoperative analgesia and emesis control in infants undergoing cataract surgery.

Detailed description: In this prospective, randomized, controlled, double blind trial eighty ASA physical status grade I and II infants (1-12month) undergoing elective cataract surgery in one eye under general anesthesia were studied. Infants were randomly allocated to one of the two groups: subtenon block Group (SB) with dexmedetomidine (n =40) or intravenous dexmedetomidine Group (IV) (n =40). After securing the airway, infants in Group (SB) received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture, whereas infants in Group (IV) received 1µ/kg IV dexmedetomidine after induction of anesthesia. Surgery started after 5 min of study drug administration. Postoperative assessment for number of infants requiring rescue analgesia and rescue antiemetics was the primary outcome. CRIES pain scale score , vomiting scale score during4-h study period, incidence of oculocardiac reflex and any surgical difficulty were the Secondary outcomes.

Eligibility criteria: Inclusion Criteria:

1. ASA physical status grade I and II infants (1-12month).
2. undergoing elective cataract surgery in one eye under general anesthesia.

Exclusion Criteria:

1. infection of the orbit,
2. increased intraocular pressure(IOP),
3. history of allergy to local anesthetics,
4. history of previous eye surgery,
5. cardiovascular or clotting disorders,
6. full stomach,inner ear disorders or other conditions predisposing to vomiting
7. airway abnormalities
8. compromised sclera.

Primary outcomes:
measure: Postoperative assessment for number of infants requiring rescue analgesia and rescue antiemetics
timeFrame: 4 hours postoperatively
measure: postoperative CRIES pain scale score
timeFrame: 4 hours postoperatively
Secondary outcomes:
measure: vomiting scale score
timeFrame: 4 hours postoperative
measure: Number of oculocardiac reflex(OCR)events(acute reduction in heart rate of >20%).
timeFrame: intraoperative period
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut Univeristy Hospital
Study officials:
References:
Clinical trial NCT01097720: Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine
Official title: Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine, Sodium Valproate, or Carbamazepine
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Autism
Developmental Delay
Birth Defects
Keywords: Valproate
Lamotrigine
Carbamazepine
Anticonvulsant
Antiepileptic
Teratogen
Autism
Developmental Delay
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2010-04-02
Enrollment: 298
Sex: ALL
Minimum age (years): 36
Maximum age (years): 83
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children 36-83 months of age, prenatally exposed to LTG, VPA, or CBZ monotherapies, recruited through mothers enrolled in the North American Antiepileptic Drug Pregnancy Registry.

Brief summary: This study is investigating the neurodevelopmental effects of prenatal exposure to lamotrigine (LTG), sodium valproate (VPA), or carbamazepine (CBZ) monotherapies. The hypotheses to be tested include:

1. Exposure during pregnancy to CBZ, LTG, and VPA, each as monotherapy, is associated with developmental delay with or without signs of autism.
2. Exposure to each drug (CBZ, LTG, and VPA) as monotherapy is associated with an increased rate of occurrence of major malformations.
3. The child with major malformations is more likely to have developmental delay with or without signs of autism than the child who does not have major malformations.
4. The occurrence of adaptive behavior outcomes will show a dose-response relationship with the dose of medication taken by the mother in the first trimester.

The study population includes children 36-83 months of age who were exposed throughout gestation to one of the three drugs of interest, as treatment for maternal seizure disorder.


Eligibility criteria: Inclusion Criteria:

* 36-83 months of age
* Prenatal exposure to LTG, VPA, or CBZ monotherapy
* AED was used by mother to suppress seizures
* Mother was enrolled in the North American AED Pregnancy Registry

Exclusion Criteria:

* Exposure during the first trimester to other known teratogens.
* Mother with mental health issues
* Refusal to release medical records to confirm eligibility.

Primary outcomes:
measure: Adaptive Behavior Scores
timeFrame: 36-83 months of age
Secondary outcomes:
measure: Presence/Absence of Major Malformations
timeFrame: 36-83 months of age
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Lewis B. Holmes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Massachusetts, Boston
name: Jane Adams, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02550574: Use of 2-octylcyanoacrylate With Full-thickness Skin Grafts
Official title: Use of 2-octylcyanoacrylate (Dermabond) During Cutaneous Wound Closure With Full-thickness Skin Grafts: a Randomized Split Wound Comparative Effectiveness Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Wound Closure Techniques
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2015-09-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether the use of 2-octylcyanoacrylate during repair of cutaneous surgery wounds with full-thickness skin grafts improves scar cosmesis compared to wound closure with sutures.

Detailed description: The purpose of this study is to determine whether the use of 2-octylcyanoacrylate during repair of cutaneous surgery wounds with full-thickness skin grafts improves scar cosmesis compared to wound closure with sutures. Our aims are to compare outcomes using a split wound model, where half of the wound is treated with 2-octylcyanoacrylate and the other half is repaired with sutures, per the standard of care. Three-months post-surgery, the scar will be measured via the physician observer scar assessment scale, a validated scar instrument. Our hypothesis is that 2-octylcyanoacrylate will result in cosmetically superior wound outcomes.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* Able to give informed consent themselves
* Patient scheduled for cutaneous surgical procedure with predicted closure with full-thickness skin graft
* Willing to return for follow-up visits

Exclusion Criteria:

* Mentally handicapped
* Unable to understand written and oral English
* Incarceration
* Under 18 years of age
* Pregnant Women
* Patients on systemic steroid therapies
* Patients with Marfans
* Patients with allergies to 2-octylcyanoacrylate

Primary outcomes:
measure: Appearance of Scar on the Patient and Observer Scar Assessment Scale
timeFrame: 3 months
Secondary outcomes:
measure: Incidence of Graft Failure on Case Report
timeFrame: 3 months
measure: Incidence of Complications on Case Report
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
affiliation: University of California, Davis
name: Daniel Eisen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01056874: Effect Of Maraviroc On The Pharmacokinetics Of Digoxin
Official title: Open-Label, Fixed Sequence, Crossover Study To Estimate The Effect Of Multiple Dose Maraviroc On Single Dose Digoxin Pharmacokinetics In Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
HIV Infections
Keywords: Maraviroc
Digoxin
P-glycoprotein
Pharmacokinetics
Drug Interaction
HIV
Lead sponsor: ViiV Healthcare
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2010-01-26
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is an open labelled study to estimate the effect of maraviroc on the pharmacokinetics of digoxin, a probe for p-glycoprotein.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive.
* Body Mass Index (BMI) of 17.5 to 25.5 kg/m2.
* Total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
* Subjects with an estimated creatinine clearance (CLcr) \<80 ml/min.
* Pregnant or nursing females.
* Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication until completion of study.

Primary outcomes:
measure: To estimate the effect of multiple dose maraviroc on the pharmacokinetics of digoxin.
timeFrame: 21 days
Secondary outcomes:
measure: To investigate the safety and tolerability of maraviroc and digoxin when co-administered.
timeFrame: 21 days
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT07019974: Imposter Syndrome in Medical Students and Its Relation With Stress
Official title: Imposter Syndrome In Medical Students And Its Relationship With Stress
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Imposter Syndrome
Medical Students
Lead sponsor: Rawalpindi Medical College
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Undergraduate MBBS students enrolled at Rawalpindi Medical University

Brief summary: The goal of this observational study is to examine the relationship between Imposter Syndrome and stress in undergraduate medical students at Rawalpindi Medical University, with particular attention to variables such as gender, academic year, and academic performance.

The main questions it aims to answer are:

Is there a positive correlation between Imposter Syndrome and stress?

Are gender and year of study associated with differences in stress and Imposter Syndrome levels?

Participants will:

Complete an online questionnaire including demographic questions

Fill out the Clance Impostor Phenomenon Scale (CIPS) to assess Imposter Syndrome

Complete the Perceived Stress Scale (PSS) to measure stress levels


Eligibility criteria: Inclusion Criteria:

* Undergraduate MBBS students enrolled at Rawalpindi Medical University
* Students from any year of study (1st to final year)
* Willingness to participate, demonstrated by providing informed consent
* Ability to complete the online questionnaire independently

Exclusion Criteria:

* Postgraduate medical students or students from other disciplines (e.g., nursing, dentistry)
* Participants with known psychiatric diagnoses (e.g., depression, anxiety disorders) that could confound stress or Imposter Syndrome assessments
* Incomplete or partially filled questionnaires
* Students who did not consent to participate in the study

Primary outcomes:
measure: Level of Imposter Syndrome among undergraduate medical students
timeFrame: May - August 2024
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Rawalpindi Medical University
state: Punjab
Study officials:
affiliation: Rawalpindi Medical College
name: Sumia Fatima, Dr
role: STUDY_CHAIR
References:
Clinical trial NCT06540274: Outcomes of Surgery for Degenerative Lumbar Spine Diseases
Official title: Outcomes and Complications of Surgery for Degenerative Lumbar Spine Diseases in Elderly Patients Above 65 Years.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Degenerative Lumbar Spine Diseases
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-08-06
Enrollment: 49
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study on the elderly patients of both genders with degenerative lumbar spine diseases.

Brief summary: The purpose of this study is to determine the effectiveness of surgery on the elderly patients with DSD.

Detailed description: This study based on observation and follow up of elderly patients underwent for surgery for degenrtative lumbar spine diseases and the effectiveness of the surgery on the quality of their life.

Eligibility criteria: Inclusion Criteria:

* Patients of both genders with age above 65 years with Low Back Pain and disability.
* Pt with clinical diagnosis of degenerative lumbar spine disease.
* Pt with MRI showing Degenerative lumbar spine disease need surgical intervention.

Exclusion Criteria:

* Patients having malignancy, vertebral fractures, trauma, inflammatory illnesses, and infection.
* Patients with degenerative conditions in the cervical and /or thoracic spine.

Primary outcomes:
measure: Visual analogue scale (VAS).
timeFrame: baseline
Secondary outcomes:
measure: Oswestry Disability Index.
timeFrame: baseline
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Mahmoud
Study officials:
References:
Clinical trial NCT02794974: Ultrasound-guided Intermediate Cervical Plexus Block
Official title: Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Endarterectomies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Internal Carotid Artery Stenosis
Lead sponsor: Helios Research Center
Sponsor class: OTHER
First posted: 2016-06-09
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators test with the present study design, whether an ultrasound-guided blockade of the cervical plexus in combination with an additional application of local anesthetic to the superficial cervical ansa (facial nerve: cervical branch) leads to an improved quality of anesthesia.

Detailed description: The innervation of the neck area is complex and includes cranial nerve (innervation of the vessel wall (IX,X) and of the neck muscles (VII,XI)), as well as the cervical plexus and brachial plexus. This is a major cause of insufficient anesthesia quality during carotid endarterectomies.

The investigators test with the present prospective study design, whether an ultrasound-guided blockade of the cervical plexus in combination with an additional application of local anesthetic to the superficial cervical ansa (facial nerve: cervical branch) leads to an improved quality of anesthesia.

Eligibility criteria: Inclusion Criteria:

* internal carotid stenosis: open surgical revascularization
* age over 18 years
* written informed consent

Exclusion Criteria:

* allergy (local anesthetics)
* pregnancy
* participation in other studies
* drug addiction
* non-cooperative patients

Primary outcomes:
measure: Local Anesthetic Supplementation (Frequency)
timeFrame: intraoperatively
measure: Local Anesthetic Supplementation (Volume)
timeFrame: intraoperatively
Secondary outcomes:
measure: Hoarseness
timeFrame: intraoperatively
measure: Cough
timeFrame: intraoperatively
measure: Dysphagia
timeFrame: intraoperatively
Other outcomes:
Locations:
city: Schwerin
country: Germany
facility: Helios Medical Center Schwerin, Department of Anaesthesiology and Intensive Care
state: Mecklenburg-Vorpommern
Study officials:
affiliation: Helios Medical Center Schwerin, Department of Anesthesiology and Intensive care,
name: Ronald Seidel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00838474: The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants
Official title: The Effect of Music by Mozart on Energy Expenditure in Growing Preterm Infants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Preterm Infants
Keywords: metabolic rate
music
preterm infants
energy expenditure
NIDCA
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-02-06
Enrollment: 20
Sex: ALL
Maximum age (years): 60
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Music has been consistently shown to reduce stress and increase weight gain in premature infants. The mechanism of this presumed improved metabolic efficiency is unknown. We aim to test the hypothesis that music by Mozart reduces energy expenditure in growing healthy preterm infants.


Eligibility criteria: Inclusion Criteria:

* appropriate weight for gestational age
* postmenstrual age of 30-37 weeks
* gavage fed
* tolerating full enteral feedings without significant gastric residuals (\>5% of total feed)
* no electrolyte imbalance

Exclusion Criteria:

* congenital anomalies
* dysmorphism
* intracranial hemorrhage of any grade
* periventricular leukomalacia
* necrotizing enterocolitis
* supplemental oxygen requirements by 28 days of age or by 36 weeks of postmenstrual age and at least 1 week prior to measurement
* active infection
* patent ductus arteriosus
* apnea of prematurity

Primary outcomes:
measure: Energy Expenditure (EE)
timeFrame: during measurment of EE
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Department of Neonatology, Tel Aviv Medcil Center
Study officials:
References:
citation: Lubetzky R, Mimouni FB, Dollberg S, Reifen R, Ashbel G, Mandel D. Effect of music by Mozart on energy expenditure in growing preterm infants. Pediatrics. 2010 Jan;125(1):e24-8. doi: 10.1542/peds.2009-0990. Epub 2009 Dec 7.